From Earlier: Forest Laboratories, Inc. and Gedeon Richter Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.
For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients. All doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks. The results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.
Cariprazine is also currently being investigated in clinical studies for patients with bipolar depression, and as an adjunct treatment for Major Depressive Disorder. Recently, results were disclosed for a third positive trial in bipolar mania.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.